RAF1 and neoplasm: Therefore, it is our conviction based on the recent developments that interventions interfering with the hyperactivation of the RAS-RAF-MEK-ERK pathway still carry great potential in the treatment of associated tumor entities, giving cause for new hope in affected patients.